Medicare’s Overdue Study On Changing EPO Payment Now Promised For 2007
Executive Summary
A rapid change in Medicare policy on reimbursement for Amgen's Epogen (epoetin alfa) used in dialysis facilities is unlikely, despite impassioned criticism of the current policy from outgoing House Ways and Means Committee Chairman Bill Thomas (R-Calif.)
You may also be interested in...
GAO Urges Congress To Place EPO, Other Dialysis Services In Bundled Rates
The Government Accountability Office recommends that Congress establish a bundled payment system for end-stage renal disease services - including Amgen's Epogen (epoetin) - under Medicare Part B "as soon as possible.
GAO Urges Congress To Place EPO, Other Dialysis Services In Bundled Rates
The Government Accountability Office recommends that Congress establish a bundled payment system for end-stage renal disease services - including Amgen's Epogen (epoetin) - under Medicare Part B "as soon as possible.
EPO Aggressive Dosing May Increase Cardiovascular Risk – NEJM Studies
Two recently published studies may curtail aggressive elevation of hemoglobin levels with erythropoiesis-stimulating agents in anemia patients